» Articles » PMID: 4118161

Lipid Absorption, Bile Acids, and Cholesterol Metabolism in Patients with Chronic Liver Disease

Overview
Journal Gut
Specialty Gastroenterology
Date 1972 Sep 1
PMID 4118161
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Faecal bile acids and neutral sterols of cholesterol origin were decreased in patients with chronic liver disease, while urinary bile acids were constantly, but never greatly, increased. Thus, production of cholesterol and its conversion to bile acids was decreased in these patients. Faecal fat was only slightly increased, even in cases with a very low bile salt output, but it was negatively correlated with faecal bile acids. The reduced capacity of these patients to synthesize bile acids was shown by the fact that cholestyramine treatment, although it decreased urinary bile acids, increased faecal bile acids only slightly. The resin constantly increased faecal neutral sterols, while the increase of faecal fat was insignificant. Thus, the absorption of fats, as compared with that of sterols, was less strongly reduced by interruption of the enterohepatic circulation of bile salts. In one cirrhotic patient markedly increased faecal bile acids apparently caused cholerrhoeic diarrhoea, which was easily controlled with cholestyramine. The latter consistently increased elimination of cholesterol in cirrhotic patients, but serum cholesterol was not consistently decreased, and in these patients, in contrast to the control subjects, it was difficult to detect changes in cholesterol synthesis with the acetate-mevalonate test and serum methyl sterols.

Citing Articles

Gut Microbiota, Peroxisome Proliferator-Activated Receptors, and Hepatocellular Carcinoma.

Yu Q, Wu L, Ji J, Feng J, Dai W, Li J J Hepatocell Carcinoma. 2020; 7:271-288.

PMID: 33150145 PMC: 7605923. DOI: 10.2147/JHC.S277870.


Dietary Polysaccharides in the Amelioration of Gut Microbiome Dysbiosis and Metabolic Diseases.

Ahmadi S, Mainali R, Nagpal R, Sheikh-Zeinoddin M, Soleimanian-Zad S, Wang S Obes Control Ther. 2018; 4(3).

PMID: 30474051 PMC: 6249025. DOI: 10.15226/2374-8354/4/2/00140.


Gut microbiota and liver diseases.

Minemura M, Shimizu Y World J Gastroenterol. 2015; 21(6):1691-702.

PMID: 25684933 PMC: 4323444. DOI: 10.3748/wjg.v21.i6.1691.


Urinary metabolite profiling offers potential for differentiation of liver-kidney yin deficiency and dampness-heat internal smoldering syndromes in posthepatitis B cirrhosis patients.

Wang X, Xie G, Wang X, Zhou M, Yu H, Lin Y Evid Based Complement Alternat Med. 2015; 2015:464969.

PMID: 25667596 PMC: 4312628. DOI: 10.1155/2015/464969.


The role of gut-liver axis in the pathogenesis of liver cirrhosis and portal hypertension.

Seo Y, Shah V Clin Mol Hepatol. 2013; 18(4):337-46.

PMID: 23323248 PMC: 3540369. DOI: 10.3350/cmh.2012.18.4.337.


References
1.
Meihoff W, KERN Jr F . Bile salt malabsorption in regional ileitis, ileal resection and mannitol-induced diarrhea. J Clin Invest. 1968; 47(2):261-7. PMC: 297168. DOI: 10.1172/JCI105722. View

2.
Hofmann A . A physicochemical approach to the intraluminal phase of fat absorption. Gastroenterology. 1966; 50(1):56-64. View

3.
Blum M, SPRITZ N . The metabolism of intravenously injected isotopic cholic acid in Laennec's cirrhosis. J Clin Invest. 1966; 45(2):187-93. PMC: 292683. DOI: 10.1172/JCI105331. View

4.
Palmer R . The formation of bile acid sulfates: a new pathway of bile acid metabolism in humans. Proc Natl Acad Sci U S A. 1967; 58(3):1047-50. PMC: 335745. DOI: 10.1073/pnas.58.3.1047. View

5.
Gregg J . Urinary excretion of bile acids in patients with obstructive jaundice and hepatocellular disease. Am J Clin Pathol. 1968; 49(3):404-9. DOI: 10.1093/ajcp/49.3.404. View